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MaTranscatheter mitral valve implantation is an emerging technology for the treatment of inoperable or high-risk patients
with symptomatic severe mitral regurgitation. Known technical issues are obstruction of the left ventricular outflow tract,
paravalvular leakage, and hemolysis. We report a case of valve retensioning successfully resolving paravalvular leakage
and hemolysis. (Level of Difficulty: Intermediate.) (J Am Coll Cardiol Case Rep 2021;3:864–70) © 2021 The Authors.
Published by Elsevier on behalf of the American College of Cardiology Foundation. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).HISTORY OF PRESENTATION
A 75-year-old male patient with severe primary mitral
regurgitation due to annular and focal calcifications
of both leaflets (Figures 1A and 1B, Videos 1 and 2)
presented with dyspnea on exertion (New York Heart
Association functional class II) and secondary pul-EARNING OBJECTIVES
To become familiar with some of the key
anatomic selection criteria for TMVI.
To learn about the specific technical issues
associated with TMVI and their management,
in particular the possibility to retension the
Tendyne valve.
To understand the importance of medical
management during and after TMVI.
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MEDICAL HISTORY
The patient underwent coronary artery bypass graft-
ing in 1993, followed by surgical aortic valve
replacement with a bioprosthesis 17 years later for
treatment of symptomatic, severe aortic stenosis.
Additional comorbidities comprised peripheral arte-
rial disease and rheumatoid arthritis requiring
chronic immunosuppressive therapy.
DIFFERENTIAL DIAGNOSIS
The differential diagnosis for dyspnea in this clinical
context includes progression of coronary artery dis-
ease, decrease of left ventricular function, pulmo-
nary hypertension, degeneration of the aortichttps://doi.org/10.1016/j.jaccas.2021.04.018
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AB BR E V I A T I O N S
AND ACRONYM S
LVOT = left ventricular
outflow tract
LVOTO = left ventricular
outflow tract obstruction
MV = mitral valve
PVL = paravalvular leak
TMVI = transcatheter mitral
valve implantation
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865bioprosthetic valve, and atrial arrhythmias (atrial
flutter or fibrillation).
INVESTIGATIONS
Progressive coronary artery disease was excluded
by coronary angiography revealing patent grafts,
and the mean invasive aortic transprosthetic
gradient was stable (14 mm Hg, planimetric aortic
valve area 1.2 cm2). The Society of Thoracic Sur-
geons risk score was 7.8%, and the European Sys-
tem for Cardiac Operative Risk Evaluation II score
was 8.1%.
A third open-heart surgical procedure was deemed
high risk by the Heart Team, and the patient was not
eligible for transcatheter edge-to-edge repair,
because of leaflet calcification in the grasping area
(Figures 1A and 1B, Videos 1 and 2). Therefore, trans-
catheter mitral valve implantation (TMVI) with the
Tendyne system (Abbott Vascular, Santa Clara, Cali-
fornia) was evaluated. The system consists of a
porcine bioprosthesis mounted in a self-expanding D-
shaped Nitinol stent fixed at the apex of the left
ventricle by a tether secured by a pad. Because of
apical fixation, the system can be retensioned using
the same surgical access. Analysis of pre-procedural
cardiac computed tomography yielded a sufficient
systolic simulated neo–left ventricular outflow tract
(LVOT) area of 285 mm2 (Figure 2A) using a 35-mm
low-profile valve placed with 6 of posterior bias
(Figures 2B and 2C).FIGURE 1 Baseline Mitral Valve Anatomy
(A) 3-dimensional view of the mitral valve from the left atrium showing fo
precluding transcatheter edge-to-edge repair. (B) 3-dimensional Dopple
nating from the calcified zone of both leaflets.MANAGEMENT
TMVI was performed under general anes-
thesia using both fluoroscopic and trans-
esophageal echocardiographic guidance.
After identification of the appropriate punc-
ture site using transthoracic echocardiogra-
phy, a left mini-thoracotomy was undertaken
in the fifth intercostal space.
Immediately after deployment of the valve
(Figures 3A and 3B), the patient experienced
acute hemodynamic deterioration with a rapid blood
pressure decrease attributable to severe LVOT
obstruction (LVOTO) mediated by anterior displace-
ment of the thickened and calcified native anterior
mitral valve (MV) leaflet (Figure 3C, Video 3).
Following administration of fluids and vasopressors
(norepinephrine) and atrialization of the valve, the
patient’s hemodynamic status quickly stabilized, and
LVOTO resolved (Figure 4).
The self-expanding mitral bioprosthesis was then
deployed (Video 4) and the tether secured at the left
ventricular apex. A slightly atrial position of the valve
with mild anterior paravalvular leak (PVL) was
accepted to ensure a sufficient LVOT area (Figure 3D,
Video 5).
A few weeks later, the patient was rehospitalized
with permanent atrial fibrillation and clinical signs of
decompensated heart failure. Hemolytic parameters
were elevated and haptoglobin was not detectable,
with a minimum hemoglobin level of 80 g/l (Figure 5).cal calcifications of the anterior and posterior valve leaflets (arrows)
r view showing an eccentric severe mitral regurgitation jet origi-
FIGURE 2 Pre-Procedural Transcatheter Mitral Valve Implantation Planning
(A) Systolic measurement of neo–left ventricular outflow tract area (green) after delineation of the mitral valve (MV) annulus and simulation
of the 35-mm (M) low-profile Tendyne valve (blue). (B) Interaction between Tendyne valve stent frame, MV calcifications, and aortic bio-
prosthesis. (C) Simulation of the Tendyne valve and tether during diastole (blue) and systole (pink).
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main reason for persistent dyspnea and cardiac
recurrent decompensation. Transesophageal echo-
cardiography showed an increase of the PVL
(Figure 6A, Video 6) related to the atrialization of the
MV bioprosthesis.
After interdisciplinary discussion, the decision was
made to perform a valve retensioning procedure us-
ing the previous thoracotomy 11 weeks after TMVI,
with the aims of reducing PVL, treating hemolysis,
and resolving symptoms. The redo procedure was
performed with a primed heart-lung machine in the
hybrid room in case of valve dislocation. Transapical
valve retrieval using a dedicated tool was trained
before the intervention. The apical pad was unlocked
and the remaining length of the tether secured with a
clamp. Under transesophageal echocardiographic
guidance, the tether was manually pulled out of the
left ventricle by 1.4 cm, which resulted in improved
apposition of the valve frame and almost abolished
the anterior PVL (Figure 6B, Video 7). No significantincrease of the LVOT gradient was observed. The
patient recovered uneventfully with rapid alleviation
of dyspnea.
DISCUSSION
Patients with significant MV disease remain largely
undertreated (1). TMVI is an emerging technology
addressing the needs of inoperable or high-risk can-
didates and represents an alternative or comple-
mentary technique to transcatheter MV edge-to-edge
repair. The efficacy and feasibility of TMVI have been
demonstrated for the treatment of severe primary
and secondary mitral regurgitation (2), as well as in
patients with severe mitral annular calcification (3).
The device obtained Conformité Européenne mark
approval in early 2020. The 2 technical issues
encountered during the reported TMVI case are
separately discussed as follows.
MANAGEMENT OF LVOTO. LVOTO is a potentially
severe complication of TMVI, and pre-operative
FIGURE 3 Valve Implantation Procedure
(A) 2-chamber view of the Tendyne valve during implantation showing annular apposition of the D-shaped atrial stent frame. (B) Left
ventricular outflow tract (LVOT) view of the Tendyne valve obtained using the x-plane function. (C) Acute LVOT obstruction during valve
implantation with imminent circulatory arrest. (D) Anterior paravalvular leak (arrow) at the end of the procedure with resolved LVOT
obstruction. IVS ¼ interventricular septum.
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Known risk factors include left ventricular hypertro-
phy, pronounced septal thickness, an aortomitral
angle of <90, a small ventricular cavity, and a long
anterior mitral leaflet (5). The complex interactions
between these anatomic structures result in the
exclusion of a considerable number of patients (60%
to 70%) at the time of screening (6). However, pre-
operative planning is not able to reliably predict
sudden changes in pre- or afterload conditions that
may occur during the procedure, as well as the dy-
namic behavior of the anterior leaflet that may result
in systolic anterior motion.
Even if infrequent, LVOTO may therefore occur
despite careful anatomic review. Medical manage-
ment during the procedure is of paramount impor-
tance and, whenever possible, is preferred over valve
repositioning. To avoid hypercontractile state and
increased heart rate, vasopressors and fluid admin-
istration should be prioritized over inotropic agents
at any time. Removal of the 34/36-F implant catheter
from the left ventricle further facilitates diastolicfilling and thereby opening of the LVOT. If these
measures are not successful, bailout maneuvers
include valve atrialization, as well as posterior
angulation to minimize the projection of the mitral
bioprosthesis into the LVOT. In our case, atrialization
of the valve after onset of hemodynamic compromise
resolved LVOTO but resulted in suboptimal annular
apposition with PVL and subsequent hemolysis.
Insufficient tether tension may also have contributed
to the mild valve loosening observed during follow-
up. Interestingly, LVOTO did not recur after valve
retensioning, which emphasizes the central role of
hemodynamic management.
MANAGEMENT OF HEMOLYSIS. Hemolysis has been
previously described as a consequence of PVL and is
more frequent in the mitral than in the aortic posi-
tion, particularly in the presence of annular calcifi-
cations (7). However, clinically relevant hemolysis
leading to symptomatic anemia is rare and was
observed in 3 of 100 patients during the Tendyne
Global Feasibility Study (8,9). In another patient,
valve retensioning was attempted to treat valve
FIGURE 4 Evolution of Hemodynamic Parameters During Tendyne Valve Implantation
ABP (s/m/d) ¼ arterial blood pressure (systolic/mean/diastolic); CVP ¼ central venous pressure; LVOTO ¼ left ventricular outflow tract
obstruction; pCO2 ¼ carbon dioxide pressure.
FIGURE 5 Evolution of Hemoglobin and Hemolytic Parameters During Therapy
Hb ¼ hemoglobin; LDH ¼ lactate dehydrogenase; TMVI ¼ transcatheter mitral valve implantation.
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FIGURE 6 Valve Retensioning Procedure
(A) Left ventricular outflow tract (LVOT) view of the Tendyne valve showing worsening paravalvular leak (PVL) (arrow) due to valve loos-
ening. (B) Improved apposition of the valve after successful retensioning with PVL abolishment and open LVOT. IVS ¼ interventricular
septum.
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case, hemolysis was explained by the appearance of a
PVL at the location of a focal calcification of the
anterior leaflet, despite a still intra-annular pros-
thesis. If retensioning remains unsuccessful, trans-
catheter PVL closure has been described and may
represent an alternative for selected patients (2,11).
FOLLOW-UP
Subsequent follow-up showed stable valve position
without recurrence of PVL and with resolution of
heart failure symptoms and relevant hemolysis
(Figure 5).
CONCLUSIONS
LVOTO and hemolysis are adverse events specific to
TMVI and require multidisciplinary management.
Medical management during implantation is of para-
mount importance for treating unexpected LVOTO
and is preferred over valve repositioning whenever
possible. Valve retensioning is feasible and can
resolve PVL as well as clinically relevant hemolysis.FUNDING SUPPORT AND AUTHOR DISCLOSURES
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